go back

Idecabtagene Vicleucel (Abecma) CAR-T Therapy

Arkansas rates for HCPCS Q2055

Idecabtagene vicleucel, up to 510 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

How much rates vary

Facilitymedian $676,083 · 10th to 90th $676,083 to $707,946Professionalmedian $676,083 · 10th to 90th $562,341 to $676,083
$1M$2Mfacility $676,083professional $676,083

Distribution of negotiated rates across all payers (price axis is log-scale). Each curve is scaled to its own total: facility and professional rates are different services, shown together to compare where they cluster. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$676,082.98
Median
$676,082.98
Typical High
$707,945.78
Aetna
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$676,082.98
Typical High
$676,082.98
United
Setting
Facility
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$562,341.33
United
Setting
Professional
Modifier
Global
Typical Low
$645,654.23
Median
$645,654.23
Typical High
$645,654.23